# Ypsomed sells pen needle and BGM business to MTD

Ypsomed has signed an agreement to transfer its pen needle and blood glucose monitoring systems businesses to Medical Technology and Devices S.p.A. (MTD). The businesses had sales of CHF 52 million in FY 2022/23.

- Type: Acquisition
- Announced: 2024-03-27
- Where: Switzerland
- Status: announced
- Products: pen needles, blood glucose monitoring systems
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Ypsomed](https://endata.com/companies/9625.md)
- [Ypsomed](https://endata.com/companies/9625.md) (target)
- [Medical Technology and Devices Group](https://endata.com/companies/67437.md) (acquirer)

## Sources

- [ypsomed.com](https://www.ypsomed.com/en/investors/ad-hoc-announcements/ad-hoc-detail-page/ypsomed-sells-its-pen-needle-and-bgm-business-to-mtd-and-invests-in-the-expansion-of-its-solothurn-site), 2024-03-27: "Ypsomed (SIX: YPSN) and Medical Technology and Devices S.p.A. (MTD) have signed an agreement on the transfer of the pen needle and blood glucose monitoring systems (BGMs) businesses."
- [medicaldevice-network.com](https://www.medicaldevice-network.com/news/ypsomed-pen-needle-mtd/), 2024-03-28: "This acquisition will enable us to accelerate growth and enter new strategic markets, leveraging a broader product portfolio combining the click technology from Ypsomed and MTD’s thinnest and shortest 34G pen needle."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.